The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Financial
  • Manufacturing
  • Music
  • Services

ExpressCells Completes Series A2 Financing
The PennZone/10119466

Trending...
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
  • L-Tron to Exhibit at PACK EXPO East Packaging and Processing Conference in Philadelphia, PA
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
Extension of Series A Supports Operations Expansion and Increased Promotion

PHILADELPHIA - PennZone -- ExpressCells, Inc., a private genetic engineering company that creates knock-in cell lines to support biological research, today announced that it has completed an extension of its Series A financing round. The company raised $590,500 in this Series A2 round from both existing and new investors. This round was oversubscribed by 18%.

New investors in ExpressCells include the MIT Alumni Angels of Northern California, the Orange County Chapter of Tech Coast Angels, and the Berkeley Angel Network. Existing investors who also invested in this round include the Rowan Innovation Venture Fund, the Central Texas Angel Network, Robin Hood Ventures, and Ben Franklin Technology Partners of Southeastern Pennsylvania.

ExpressCells is using the $590,500 raised in this round to expand its operational infrastructure to support the increasing demand for its knock-in cell lines. The company also will increase promotion to the biological research community.

More on The PennZone
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • STATEMENT: Shincheonji on Religious Freedom Controversy
  • Cyntexa Outlines a Principles-first Approach to Modern Enterprise Transformation
  • Kickstarter And Creator Camp Partner To Support A New Era Of Creator-led Independent Film
  • Top 66 People-Centric Leaders of 2025 Prove Taking Care of People Is Taking Care of Business

"This funding allows ExpressCells to meet the rapidly-growing demand from both industry and academic customers. We are thankful to the new investors who have joined our Series A," said Matt Handel, co-founder and CEO of ExpressCells. "We also appreciate the additional funding from our existing investors."

Interest in this round of financing was driven, in part, by recent news events for ExpressCells. Pepperdine Graziadio Business School named ExpressCells to its 2020 Most Fundable Companies® List and ExpressCells was one of top three startups—and the top life sciences company—in the Pismo Venture's National Venture Plan Competition.

About ExpressCells

ExpressCells uses its proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other types of biological research. The speed of the process allows ExpressCells to insert one to three genes into the same cell line months faster than other technologies. The company currently has 17 customers and expects that number to grow.

ExpressCells sells both custom and catalog cell lines. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
ExpressCells, Inc.
***@xpresscells.com


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • MAX Illumination Redefines Cabinet Displays with New Edge-Lit LED Technology
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • FeedSocially - Post Once, Publish Everywhere
  • Finland's New Gambling Watchdog Handed Sweeping Powers to Revoke Licenses and Block Illegal Casino Sites
  • James D. Harding Promoted to Century Fasteners Corp. – Managing Director
  • Powering the AI, Defense and Aerospace Future with Energy Infrastructure and Digital Asset Strength: KULR Technology Group, Inc. $KULR
  • $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
  • Poolvillas Expands Local Presence on the Costa Blanca with New Offices in Moraira and Denia – Over 30 Years of Expertise Now Even Closer to Guests
  • Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
  • OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
  • Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio
  • MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
  • Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
  • Perry County Real Estate Agency Partners with Internet Marketing Company
  • Philadelphia HVAC Companies Were Not Created Equal
  • Home Prices Just Hit 5X Median Income — So Americans Are Buying Businesses Instead of Houses
  • Briggs Auction's Jan. 30 online Fine Estates Auction features artworks by Hans Hoffman, Hans Coper, Lucie Rie, Loet Vanderveen
  • Peak Exteriors LLC to Open First Office in East Berlin in 2026

Popular on PennZone

  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 237
  • Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
  • Appliance EMT Expands Professional Appliance Repair Services to Hartford, Connecticut
  • Pawprint Oxygen Turns Pet Safety Viral With "Pets Live Here" Window Decals — Helping First Responders Save Lives
  • Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • OneSolution® Expands to Orlando with New Altamonte Springs Implant Center
  • TheOneLofi2: New Home for Chill Lo-Fi Hip Hop Beats Launches on YouTube
  • Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
  • eJoule Inc Participates in Silicon Dragon CES 2026

Similar on PennZone

  • SNS Research Launches SNS Market Intelligence Platform for visual market intelligence for pharma
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us